Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Atossa Therapeutics Inc’s stock clocked out at $0.85, up 2.48% from its previous closing price of $0.83. In other words, the price has increased by $2.48 from its previous closing price. On the day, 0.59 million shares were traded.
Ratios:
To gain a deeper understanding of ATOS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 12.67 and its Current Ratio is at 12.67. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on January 26, 2018, initiated with a Buy rating and assigned the stock a target price of $2.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 21 ’25 when QUAY STEVEN C bought 11,239 shares for $0.88 per share. The transaction valued at 9,887 led to the insider holds 13,898 shares of the business.
Remmel H. Lawrence bought 10,000 shares of ATOS for $7,000 on Mar 26 ’25. The Director now owns 10,257 shares after completing the transaction at $0.70 per share.
Stock Price History:
Over the past 52 weeks, ATOS has reached a high of $1.66, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is 6.52%, while the 200-Day Moving Average is calculated to be -17.60%.
Shares Statistics:
A total of 129.17M shares are outstanding, with a floating share count of 129.12M. Insiders hold about 0.04% of the company’s shares, while institutions hold 26.47% stake in the company.
